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Abstract  
Background: Germline variants in MC1R may increase risk of childhood/adolescent 
melanoma, but a clear conclusion is challenging because of the limited number of studies and 
cases. We evaluated the association of MC1R variants and childhood/adolescent melanoma 
in a large study comparing the prevalence of MC1R variants of childhood/adolescent 
melanoma patients to that among adult melanoma cases and unaffected controls.  
Methods: Phenotypic and genetic data on 233 childhood/adolescent (≤20 years) and 932 adult 
melanoma patients, and 932 unaffected controls, were gathered through the M-SKIP Project, 
the Italian Melanoma Intergroup and European centers. We calculated odds ratios (OR) for 
childhood/adolescent melanoma associated with MC1R variants by multivariable logistic 
regression. Subgroup analysis was done for children aged ≤18 and ≤14 years. 
Findings: Children and adolescents had a higher odds of carrying MC1R r variants than adults 
(OR:1·54; 95%CI:1·02-2·33), also when analysis was restricted to cases ≤18 years (OR:1·80; 
95%CI:1·06-3·07). All the investigated variants except R160W showed a higher frequency in 
childhood/adolescent melanoma compared to adult melanoma, with significant results for V60L 
(OR:1·60; 95%CI:1·05-2·44) and D294H (OR:2·15; 95%CI:1·05-4·40). Compared to 
unaffected controls, childhood/adolescent melanoma patients had significantly higher 
frequencies of any MC1R variants. . 
Interpretation: Our pooled-analysis of childhood/adolescent patients with MC1R genetic data 
revealed that MC1R r variants were more prevalent in childhood/adolescent compared to adult 
melanoma especially in children ≤18 years. Our findings support the role of MC1R in 
childhood/adolescent melanoma susceptibility with a potential clinical relevance in developing 
early melanoma detection and preventive strategies. 
Funding: SPD-Pilot/Project-Award-2015; AIRC-MFAG-11831. 
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Introduction 
Cutaneous Melanoma (CM) mainly occurs in patients of adult age and is rare in the 
pediatric population, with only 2% of all CM cases diagnosed in patients younger than 20 years. 
1-4 In the childhood/adolescent population, the majority of CM are diagnosed among 
adolescents and only 8% occur in infancy and childhood.5,6  
Differences exist in clinical aspects, histopathological features and disease staging 
comparing childhood/adolescent CM to adult CM.2,7-8 CM in childhood is often amelanotic, 
shows broad histopathological variability and may present with histologic uncertainty and 
ambiguous atypical characteristics that do not allow a definite malignant or benign 
classification.4,9 Children with CM present at a more advanced stage of disease with thicker 
lesions and higher rates of lymph node metastasis than their adult counterparts, leading to a 
worse prognosis.4,9 However, published studies report discordant data on survival rates.5,10 
It has long been debated whether adult and childhood/adolescent melanomas share a 
similar pathogenesis. Major risk factors for pediatric CM are giant congenital melanocytic nevi 
and hereditary conditions including xeroderma pigmentosum, immunodeficiency, and 
albinism.11 Other known risk factors common to pediatric and adult melanoma are family 
history of melanoma, dysplastic nevus syndrome, elevated number of acquired melanocytic 
nevi, red hair, sun-sensitive phenotype, and UV exposure.12-13 
It is uncertain whether childhood/adolescent CM differs from adult CM with regard to 
genetic predisposition. Pediatric CM is mostly sporadic, while adolescent CM is sometimes 
observed in melanoma-prone families. In general, there is a higher proportion of germline 
mutation carriers among young cancer patients,14 but whether this tendency holds true for CM 
is unclear due to the rarity of childhood/adolescent CM. Based on the few available studies, , 
childhood/adolescent patients have only rarely been found to carry germline mutations in the 
two high-penetrance melanoma genes, CDKN2A  and CDK4 12,15-21 that are known to be 
significantly associated to melanoma only in a familial and not in a sporadic context. 
The MC1R (melanocortin-1 receptor) gene is a key determinant of human 
pigmentation.22 MC1R is highly polymorphic in the general population and specific variants 
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were defined as “R” (D84E, R142H, R151C, I155T, R160W, D294H) or ‘r’ (V60L, V92M, 
R163Q) alleles according to the strength of association with the red hair color (RHC) 
phenotype.23 Extensive in vitro and in vivo evidence showed that both R and r alleles produce 
hypomorphic proteins with compromised activity compared with native MC1R function.22 The 
R alleles are reported to have major impact on pigmentation and UV-sensitivity.22,23 In contrast, 
r variants confer normal or slightly impaired MC1R activity resulting in a low strength 
association with the fair skin phenotype.23  
Natural variation at MC1R is an established risk factor for CM across multiple 
populations worldwide.24 Risk of CM is higher for carriers of MC1R variant than for wild-type 
individuals, with the strongest association among carriers of R alleles and multiple variants.24 
MC1R variants confer a significant increased risk in darkly pigmented individuals, highlighting 
the impact of MC1R through non-pigmentary pathways.25,26 Moreover, MC1R genotype is 
associated with phenotypic characteristics of melanoma27 and melanocytic nevi28 and seems 
to influence the somatic mutational load in adult CM.29 
Childhood/adolescent CM patients have an elevated prevalence of MC1R variants, but 
the limited number of available studies coupled to the small number of cases per study makes 
challenging to draw clear conclusions.18-20  
To help elucidate the role of MC1R in childhood/adolescent CM and to better 
understand the genetic and clinical diversity of childhood/adolescent and adult CM with 
potential clinical impact in terms of early melanoma detection and preventive strategies, we 
assessed these tumors in a large multicenter pooled dataset established from the Melanocortin 
1 receptor SKin cancer and Phenotypic characteristics (M-SKIP) Project, the Italian Melanoma 
Intergroup (IMI) and other European groups. The endpoints of our study were: (1) to compare 
the prevalence of MC1R variants between childhood/adolescent cases and unaffected controls 
with a case-control study design and (2) between childhood/adolescent and adult CM patients 
using a case-case study design. 
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Material and Methods 
Study population 
Our analysis included children and adolescents diagnosed with sporadic single-primary 
CM at age ≤20 years, adult cases with sporadic single-primary CM at age ≥35 years and 
unaffected adult controls. Since age is a continuous variable and an exact age cut-off between 
adolescents and adults would not be expected, we excluded melanoma cases diagnosed in 
the age range 21-34 years to avoid a possible overlap between categories and thus enable 
comparison between groups with distinct clinical and genetic characteristics. 
 Because of the known challenges in diagnosing pediatric melanoma30-32 and to 
decrease misdiagnosis, participating investigators were asked to provide the original 
histopathological reports and representative glass slides for central review. Only patients for 
whom the original histopathological report was available were eligible. In addition, we restricted 
the study to cases with complete MC1R genotyping. We excluded familial melanoma cases,  
cases with a history of cancer at any site other than non-melanoma skin cancer, atypical 
spitzoid neoplasms/MELanocytic Tumors of Uncertain Malignant Potential, ocular and 
mucosal melanomas. 
Detailed information on recruitment is reported in the Appendix, pp 1-2. Ethics 
Committee approval was obtained at each institution in which new blood samples were drawn. 
For each childhood/adolescent CM case, four adult CM cases and four controls were randomly 
selected from the same parent study that gave rise to the childhood/adolescent case. When 
this was not possible, adult cases and controls were selected from a study that was conducted 
in the nearest geographical proximity to the parent study of the childhood/adolescent case 
(Appendix, pp 1-2 and Appendix, pp 5-6). A geographical representation of the recruitment 
area of childhood/adolescent cases, adult cases and controls is shown in Figure 1. 
Overall, we retrospectively collected data on 367 childhood/adolescent cases, 8,582 
adult CM cases, and 5,770 controls (Figure 1). For 59 childhood/adolescent patients, 
information on MC1R was not available either because of patients’ death (N=2) or refusal to 
participate in the study (N=57). Among the remaining 308 patients, 75 had no original 
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histopathological report available, leaving 233 children/adolescent cases for inclusion in the 
statistical analysis. For the selected 932 adult cases, 474 arose from the same parent study 
as the childhood/adolescent case and 458 came from a geographically close study population. 
For the selected 932 controls, 354 arose from the same parent study as the 
childhood/adolescent cases and 578 came from a geographically close study population. 
 
Molecular analysis 
For 135 childhood/adolescent patients from M-SKIP and 48 from IMI/European centers, 
MC1R sequencing had already been performed in study-specific laboratories (Appendix, pp 5-
6). For the remaining 50 childhood/adolescent patients from IMI/European centers who 
provided new blood or saliva samples, MC1R genotyping was centralized at the University of 
L’Aquila and performed as previously described.33 
 
Statistical analysis 
A complete description of the statistical analysis is presented in the Appendix, pp. 2-4. 
Briefly, the associations between risk factors and childhood/adolescent melanoma were 
analyzed by logistic regression in comparison with two reference groups, (1) adult cases and 
(2) unaffected controls, with adjustment for study/geographical location.  
The frequency of any MC1R variants among children/adolescents was compared to 
that among adults and controls by logistic regression with adjustment for study/geographical 
location. These comparisons were repeated for any MC1R R variant, any r variant, a score 
calculated by summing across the MC1R alleles giving a value of 1 to “r” and 2 to “R” variants, 
as previously proposed,34 and for each of the nine most prevalent MC1R variants and of any 
rare MC1R variants (presence/absence). We then used multivariable unconditional logistic 
regression models to calculate the odds ratio (OR) for MC1R variants after adjusting for 
study/geographical location and other covariables (as available), including sex, melanoma 
body site, histopathological subtype, hair color, and skin type. Sensitivity analysis with 
multivariable conditional logistic regression models was also performed. 
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The primary analysis compared the entire sample of childhood/adolescent cases to 
controls and adult cases. In order to take into account the possible misdiagnosis in 
childhood/adolescent cases, we repeated the primary analysis including only the subgroup of 
childhood/adolescent patients with CM diagnosis confirmed after central slide review; and then 
we calculated a modified ORs, applying the method proposed by Green35 that incorporates 
adjustment based on the predictive value of a positive test.  
Sensitivity analysis on the subgroup of childhood/adolescent and adult cases arising 
from the same parental study, and after the exclusion of patients without confirmed diagnosis 
were also conducted. Subgroup analyses were done according to age at diagnosis of 
childhood/adolescent cases.  
Generally, p-values <0·05 were considered statistically significant. However, we also 
calculated False Discovery Rate (FDR) corrected p-values to take into account multiple 
comparisons.  
 
Role of the funding source 
No sponsor had role in study design, data collection, data analysis, data interpretation, 
or writing of the report. 
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Results 
Table 1 report populations’ characteristics. Briefly, median age (interquartile range) was 
18 years (15-19) in the children/adolescent case group, 55 years (45-67) in the adult case 
group and 50 years (43-59) in the control group. Among childhood/adolescent cases, 52 (22%) 
were aged ≤14 years, 96 (41%) between 15 and 18 and 85 (37%) >18. The total count of 
common melanocytic nevi was higher among childhood/adolescent patients [30 (range 15-64)] 
than among either adult patients [25 (10-45)] (P=0.0007) or controls [21 (5-30), P<0.0001]. A 
higher proportion (43%) of children/adolescents cases had atypical melanocytic nevi than did 
adult cases (32%) and controls (9%) (P=0.01 and P<0.0001, respectively). Five percent and 
11% of melanomas occurred on the upper limbs and 34% and 29% on the lower limbs in 
children/adolescents and adults, respectively (P=0.04). A spitzoid melanomas was identified 
in 13 (7%) childhood/adolescent cases compared to 2 (0%) adult cases; 21 (11%) 
children/adolescents had other specified types of melanoma compared with 8 (1%) adult cases 
(P<0.0001). Children/adolescents less frequently (36%) had blue eyes compared to adults 
(50%; P=0.01) or controls (47%, P<0.0001), and they were less likely (15%) to have solar 
lentigines than adults (75%, P<0.0001) and controls (68%, P<0.0001). 
Table 2 shows frequencies of any MC1R variants, any R variants, any r variants, MC1R 
score and any of the nine most prevalent MC1R variants in 233 childhood/adolescent cases, 
932 adult cases and 932 controls. In univariable analysis, no significant differences were 
observed in frequency of MC1R variants between childhood/adolescent and adult cases. 
However, childhood/adolescent cases had significantly higher frequency of any variants, R 
variants, r variants and MC1R score than unaffected controls, confirming the role of MC1R in 
melanoma susceptibility. Eight rare MC1R variants were found in childhood/adolescent 
patients: 86insA (N=2), V51A, T95M, V122M, R151H, A218T, F258L, K278E, (N=1 each). No 
association was found between childhood/adolescent melanoma and any MC1R rare variant 
(data not shown). 
Among the 233 childhood/adolescent cases, representative histopathological slides of 
the tumor were available for 85 patients and were centrally reviewed for quality control by one 
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dermatopathologist (D.M.). The group of 85 patients had similar clinico-pathological 
characteristics compared to the 148 for whom glass slides were not reviewed (Appendix p 7). 
The original diagnosis of melanoma was confirmed in 64/85 (75%) cases. The remaining slides 
from 21/85 (25%) cases were deemed as not being representative or difficult to interpret for 
technical reasons, or were reclassified as atypical melanocytic nevi, atypical junctional 
melanocytic proliferations, pagetoid melanocytosis overlying congenital nevi, or ambiguous 
atypical melanocytic proliferations with spitzoid features. In the latter cases, serial unstained 
slides or paraffin blocks were not available and so additional immunohistochemical and/or 
molecular analyses which would have clarified interpretation were precluded. Such doubtful 
cases were independently reviewed by a second dermatopathologist (F.F.); the conflicting 
discrepancy with the original diagnosis remained unresolved. The median Breslow thickness 
(interquartile range) was 1·00 mm (0·50-1·90) for the 64 cases with a confirmed diagnosis and 
0·45 mm (0·10-0·75) for the 21 cases in which the original diagnosis was not confirmed 
(P=0·0005, Appendix p 8). No other clinico-pathological features differed between the two 
groups (Appendix p 8). 
The frequencies of MC1R variants in the subgroup of 64 children/adolescents with a 
confirmed diagnosis after histopathological review, 254 adults, and 254 controls are shown in 
Table 2 and are similar to those reported for the primary analysis (Table 2).  
The OR (95%CI) for the 233 children/adolescent CM cases and 932 adult CM cases 
(OR all patients), for the subgroup of 64 children/adolescent CM cases with a confirmed 
diagnosis after review and 256 adult CM cases (OR confirmed diagnosis) and after correction 
by the estimated outcome misclassification rate (corrected OR) are shown in Figures 2 and 3. 
We found that children/adolescent melanoma had a significantly higher odds of carrying any r 
variants compared to adult cases (OR: 1·54; 95%CI: 1·02-2·33, FDR-corrected P=0·17, Figure 
2). Concerning specific MC1R variants, we found a positive association for all MC1R variants 
with childhood/adolescent melanoma, except for the R160W variant (Figure 3). A statistically 
significant association for V60L and D294H variants (OR: 1·60; 95%CI: 1·05-2·44, FDR-
corrected P=0·17, and OR: 2·15; 95%CI: 1·05-4·40, FDR-corrected P=0·17) was found in the 
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primary analysis and after correction for possible misdiagnosis. Similar results were obtained 
in sensitivity analysis with conditional logistic regression models (Appendix p 8) and by 
excluding the 21 children/adolescents without centrally confirmed diagnosis (Appendix p 9). 
Finally, when we repeated the primary analysis on the subgroup of childhood/adolescent and 
adult cases arising from the same parental study, we obtained even stronger associations for 
carriers of any MC1R variant (OR: 2·04 95% CI: 1·19-3·50), r variants (OR: 2·61 95% CI: 1·43-
4·73), V60L (OR: 2·67 95% CI: (1·44-4·95) and D294H variants (OR: 3·12 95% CI: 1·08-9·03) 
(Appendix p 11). 
Table 3 lists OR (95%CI) calculated for childhood/adolescent cases ≤18 and ≤14 years 
of age. A statistically significant higher frequency of r variants was observed in cases ≤18 years 
of age compared to adults (OR: 1·80; 95%CI: 1·06-3·07, FDR-corrected P=0·61). The 
corresponding OR for cases ≤14 years was even higher, but did not reach statistical 
significance because of the small number of subjects. 
Appendix pp 12-13 show the ORs (95%CI) obtained for the case-control analysis 
comparing childhood/adolescent melanoma patients with controls. Regarding OR obtained 
from the primary analysis, we found a significantly higher risk of childhood/adolescent 
melanoma for carriers of any MC1R, R, r and the most common MC1R V60L, V92M, R151C, 
R163Q and D294H variants. Results remained statistically significant after correction for 
multiple comparison except for the V92M variant (FDR-corrected P=0·07). 
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Discussion 
Our pooled-analysis showed that MC1R variants are a genetic risk factor for 
childhood/adolescent CM and that the frequency of r variants is elevated in this young case 
group compared to adult CM cases. The impact of r alleles was confirmed in analyses limited 
to individuals ≤18 years and was even stronger for children ≤14 years, although this difference 
was not statistically significant. The MC1R V60L and D294H variants showed the most robust 
association with melanoma in childhood and adolescence, even after correction for possible 
misdiagnosis. 
Childhood/adolescent melanoma has been reported to occur most commonly in whites 
and in females.2,10,13 In line with two previous studies, we found that childhood/adolescent 
melanoma patients are characterized by a fairer phenotype compared to healthy controls,12,13 
including traits such as red hair and skin type. In contrast, when compared to location-matched 
adult cases, childhood/adolescent patients presented with more darkly pigmented 
characteristics such as brown eyes, skin type III-IV and a lower prevalence of freckles. 
Consistent with the majority of published studies, our childhood/adolescent patients showed a 
high number of melanocytic nevi, both common and atypical, and developed melanomas 
mainly on the lower extremities and the trunk.2,11,36 Childhood/adolescent melanoma was more 
commonly diagnosed as nodular melanoma compared to the adult counterpart. Spitzoid 
melanomas were more frequently identified in childhood/adolescent patients, while LMM were 
only seen in adulthood.., 
The impact of MC1R alleles in childhood/adolescent melanoma was investigated in 
small series of patients.18-20 MC1R variants were identified in 12/21 (57%) patients, with a 
higher frequency of r compared to R allele by Daniotti et al. (2009).19 More recently, two case 
series reported MC1R variants in 10/23 patients (43%)18 and in 4/6 patients (67%).20 In our 
pooled-analysis, MC1R variants were detected in 75% of childhood/adolescent patients. 
Overall, multivariable analysis suggested that childhood/adolescent cases had greater odds to 
carry any MC1R variant and a significantly greater odds to carry r variants compared to adult 
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cases. Interestingly, the odds of carrying r alleles increased in subgroup analysis limited to 
adolescents ≤18 years old, and was stronger still (although not statistically significant) among 
cases ≤14 years old, suggesting a higher prevalence of the MC1R variants in childhood 
melanoma.  
Our findings demonstrate a stronger role of MC1R r variants in childhood/adolescent 
than in adult melanoma, suggesting the involvement of biological pathways other than 
pigmentation and UV-sensitivity such as antioxidant defenses, DNA repair and cell proliferation 
.22,24,37 Indeed, MC1R signaling is crucial for melanocyte key processes 38, as suggested by 
the findings of Baron al (2014), demonstrating that MC1R variants combined with HERC2/ 
OCA2 alleles determine the number of nevi >2 mm in sunburned kids.39 
Herein the MC1R variants V60L and D294H showed significantly higher prevalence in 
childhood/adolescent compared to adult melanoma. The role of V60L in adult melanoma is 
controversial and the magnitude of risk varies across populations.40 A positive association of 
V60L with melanoma has been reported in the Mediterranean area, where this variant is the 
most frequent .40 The D294H variant is common in individuals with the RHC phenotype. The 
association of D294H with melanoma risk demonstrates heterogeneity between Northern 
versus Southern European populations, where individuals who are more darkly pigmented are 
at higher risk of melanoma associated with D294H than Northern populations.41  
To the best of our knowledge, our series of childhood/adolescent melanoma patients is 
the largest worldwide multicenter cohort published so far with available MC1R genetic data. 
The large number of childhood/adolescent and comparable adult melanoma patients provide 
powerful estimates of the association between MC1R variants and childhood/adolescent 
melanoma within different populations. A further strength of our study was centralized data 
quality control and statistical analysis that provided consistency across the numerous parent 
studies in defining and adjusting for important covariates. Histopathological centralized review 
of one third of the subjects allowed us to calculate association estimates in a subset of 
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children/adolescents with a histologically confirmed diagnosis and was helpful to calculate 
corrected risk estimates taking into account the issue of misdiagnosis. 
Childhood/adolescent melanoma patients represent a heterogeneous group, including 
neonates, children and adolescents, with a variety of distinct presentations.9 Childhood 
melanoma may indeed differ from adolescent melanoma and both may differ from adult 
melanoma.4, To further address heterogeneity between melanomas developed at different 
ages, we performed a stratified analysis for patients ≤14  and ≤18 years. Our non-significant 
findings among cases ≤14 years may have resulted from decreased power related to the small 
sample size (N=59) of this group, while a separate multivariable analysis limited to children 
≤10 years of age was not possible due to the limited number of patients (N=23). In our 
childhood/adolescent sample we had more darkly pigmented cases from Southern European 
compared to Northern European origin, which may have resulted in relatively high frequencies 
of r variants, more common in Southern than in Northern Europe.42 However, because 
childhood/adolescent cases were compared with adult cases and controls from the same 
geographical areas, we do not believe this affected our results. Indeed, sensitivity analysis 
conducted in the subgroup of childhood/adolescent cases with adult cases sampled from the 
same parent study provided similar results. A centralized review of all melanomas would be 
desirable, but unfortunately it was not feasible due to the retrospective nature of the study. In 
order to limit disease misclassification, we excluded from the analysis patients whose 
histopathological reports were not available. We also provided risk estimates corrected for our 
observed misclassification rate among patients with histopathological centralized review, a 
group that was representative of the entire cohort of childhood/adolescent patients. 
Nevertheless, it should be noted that this correction could not be able to provide an exact 
estimate of the associations as in a sample with only centrally confirmed diagnosed cases, 
and a certain imprecision of estimates could therefore not be ruled out. Because our cohort 
did not include familial melanoma patients and the major susceptibility genes are rarely 
mutated in childhood/adolescent cases,12,15,17,20 we did not analyze CDKN2A and CDK4 in our 
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patients. It is possible that other major melanoma predisposition genes may influence the risk 
of disease in children/adolescents, but lack of genetic data on these genes, such as the BAP1 
gene prevented the analysis of possible gene–gene interactions. Finally, although we 
performed a relatively high number of statistical tests, we allowed unadjusted P-values to guide 
the interpretation of our results. Given the exploratory rather than confirmatory nature of this 
study, we believe that our approach of describing the tests of significance we performed, as 
advised by Perneger (1998),43 is appropriate. However, to directly address the issue of multiple 
testing, we also present FDR-corrected P-values. 
In conclusion, our pooled analysis showed that natural variation at MC1R is a genetic 
risk factor for childhood/adolescent CM as well as for adult CM. A major role of MC1R variants, 
mainly r alleles, was suggested in childhood/adolescent compared to adult melanoma, possibly 
through a pigmentation-independent pathway. In addition, we observed a stronger effect of the 
r alleles when the analysis was restricted to melanoma patients aged less than 18 years. 
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FIGURE LEGENDS 
Figure 1. Flow chart of melanoma cases included in the analysis and their geographical 
area of recruitment. A, adult melanoma patients; Ch/Ad, children/adolescents melanoma 
patients; CM, cutaneous melanoma; Co, unaffected controls; MC1R, melanocortin-1 receptor 
gene. 
 
Figure 2. Covariable-adjusted OR (95%CI) for the association between any MC1R 
variants, R and r variants and childhood/adolescent melanoma compared to adulthood 
melanoma.  
All the OR were adjusted by sex, matching stratum variable, melanoma body site and 
histopathological subtype, hair color and skin type. For each OR, the comparison groups 
included childhood/adolescent patients frequency matched 4:1 with adult cases by 
study/geographical area. The reference category for OR were MC1R wild-type (WT) subjects. 
Number of children/adolescents and adults reported here are the total number of subjects 
included in each analysis, independently by MC1R status. Note that for the analysis on any R 
variant vs WT, subjects carrying only r variants were excluded, and vice versa for the analysis 
on any r variant vs WT.  
aOR calculated on the subgroup of subjects with confirmed diagnosis of melanoma after 
centralized pathological review of glass slides. bOR calculated on the whole sample of N=233 
childhood/adolescent cases. cOR corrected by probability of misdiagnosis combining 
information from OR(a) and OR(b) as previously suggested.35 
MC1R, melanocortin-1 receptor; CI, Confidence Intervals; OR, Odds Ratio. R variants include 
the D84E, R142H, R151C, I155T, R160W, D294H and other rare variants classified as R 
according to the algorithm proposed by Davies et al (2012);34 r variants include the V60L, 
V92M, R163Q and other rare variants classified as r according to the algorithm proposed by 
Davies et al (2012).34 
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Figure 3. Covariable-adjusted OR (95%CI) for the association between the nine most 
prevalent MC1R variants and childhood/adolescent melanoma compared to adulthood 
melanoma.  
All the OR were adjusted by sex, matching stratum variable, cancer body site and histological 
type, hair color and skin type. For each OR, the comparison groups included 
childhood/adolescent patients frequency matched 4:1 with adult cases by study/geographical 
area. The reference category for OR were MC1R wild-type (WT) subjects. Number of 
children/adolescents and adults reported here are the total number of subjects included in each 
analysis, independently by MC1R status. Note that for the analysis on each variant vs WT, 
subjects carrying only other MC1R variants were excluded.  
aOR calculated on the subgroup of subjects with confirmed diagnosis of melanoma after 
centralized pathological review of glass slides. bOR calculated on the whole sample of N=233 
childhood/adolescent cases. cOR corrected by probability of misdiagnosis combining 
information from OR(a) and OR(b) as previously suggested.35 
MC1R, melanocortin-1 receptor; CI, Confidence Intervals; NC, not calculable; OR, Odds Ratio. 
R variants include the D84E, R142H, R151C, I155T, R160W, D294H and other rare variants 
classified as R according to the algorithm proposed by Davies et al (2012); r variants include 
the V60L, V92M, R163Q and other rare variants classified as r according to the algorithm 
proposed by Davies et al (2012).34 
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